INmune Bio Reports Promising Phase I/II Trial Results
PremiumCompany AnnouncementsINmune Bio Reports Promising Phase I/II Trial Results
1M ago
INmune Bio price target raised to $30 from $22 at Maxim
Premium
The Fly
INmune Bio price target raised to $30 from $22 at Maxim
2M ago
INmune Bio opens Phase II in high dose cohort of INKmune trial
Premium
The Fly
INmune Bio opens Phase II in high dose cohort of INKmune trial
2M ago
INmune Bio announces plans to submit FDA BLA for CORDStrom
PremiumThe FlyINmune Bio announces plans to submit FDA BLA for CORDStrom
2M ago
INmune Bio expands INKmune trial in prostate cancer to veterans
Premium
The Fly
INmune Bio expands INKmune trial in prostate cancer to veterans
2M ago
INmune Bio initiated with a Buy at Rodman & Renshaw
Premium
The Fly
INmune Bio initiated with a Buy at Rodman & Renshaw
2M ago
INmune Bio, OmniScience partner to accelerate trial with Vivo
PremiumThe FlyINmune Bio, OmniScience partner to accelerate trial with Vivo
4M ago
INmune Bio announces enrollment of 208 patients in Phase 2 trial of early AD
Premium
The Fly
INmune Bio announces enrollment of 208 patients in Phase 2 trial of early AD
5M ago
Inmune Bio Emerges as Biotech Innovator in 2023
Premium
Company Announcements
Inmune Bio Emerges as Biotech Innovator in 2023
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100